Levofloxacin Stada (Levofloxacin)

Levofloxacin acts by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. This blockade prevents the unwinding and resealing of DNA strands, leading to halted bacterial growth and ultimately bacterial cell death.

The dosage of Levofloxacin Stada is determined by the prescribing healthcare professional based on the specific infection, patient characteristics, and local guidelines. Only a qualified prescriber should set the dose and duration of therapy.

Levofloxacin Stada should only be used during pregnancy or while breastfeeding if the potential benefits outweigh the possible risks to the fetus or infant. The decision must be made by a qualified healthcare provider after careful assessment.

To request Levofloxacin Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Levofloxacin belongs to the fluoroquinolone class, offering broad‑spectrum activity against many Gram‑negative and Gram‑positive bacteria. Compared with beta‑lactam antibiotics, it often provides once‑daily oral dosing and good tissue penetration, but it carries class‑specific risks such as tendon toxicity and QT prolongation that must be weighed against its benefits.

Levofloxacin Stada should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, and store it out of direct sunlight to maintain stability.

Levofloxacin Stada is administered orally, typically as a tablet or capsule taken with or without food, according to the prescriber's instructions. The exact form and dosing schedule should follow the healthcare professional’s guidance.

Serious risks include tendon rupture (especially in the Achilles tendon), QT interval prolongation that can lead to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Patients should be monitored for these events, and therapy should be discontinued if they occur.

Levofloxacin Stada should be avoided in individuals with a known hypersensitivity to fluoroquinolones, those with a history of tendon disorders related to fluoroquinolone use, patients taking concomitant medications that significantly prolong the QT interval, and in pregnant or breastfeeding women unless clearly indicated by a healthcare professional.